Clinical Trials Browser

Phase 2 × Lymphoma, Large B-Cell, Diffuse × sintilimab × Clear all

NCT05280626 2022-03-15

First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOP

Phase 2 Not yet recruiting

Lymphoma, Large B-Cell, Diffuse

NCT04659434 2020-12-09

Sintilimab Plus R-GemOx as Second-line Salvage Therapy in Patients With R/R DLBCL

Phase 2 Unknown

Lymphoma, Large B-Cell, Diffuse